# ACCEPTABILITY AND WRITING FREQUENCY OF ADVANCED DIRECTIVES IN ONCO-DERMATOLOGY PATIENTS

> **NCT03822988** · — · UNKNOWN · sponsor: **Central Hospital, Nancy, France** · enrollment: 150 (estimated)

## Conditions studied

- Advance Directives
- Oncology
- Skin Cancer
- Melanoma
- Skin Lymphoma
- Skin Squamous Cell Carcinoma
- Metastatic Basal Cell Carcinoma

## Interventions

- **OTHER:** no intervention, only complete a survey

## Key facts

- **NCT ID:** NCT03822988
- **Lead sponsor:** Central Hospital, Nancy, France
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-21
- **Primary completion:** 2019-06-20
- **Final completion:** 2019-06-20
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2019-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03822988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03822988, "ACCEPTABILITY AND WRITING FREQUENCY OF ADVANCED DIRECTIVES IN ONCO-DERMATOLOGY PATIENTS". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03822988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*